LUX-Lung 5 was a multicenter phase III study completed in 2014 which aimed to assess the efficacy of afatinib plus paclitaxel versus single-agent chemotherapy in patients with relapsed/refractory NSCLC with mutations occurring in the EGFR gene after erlotinib/gefitinib therapy [53]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.